Abstract 448P
Background
Metastatic hormone receptor-positive (HR+)/human epidermal growth factor receptor-2-negative (HER2-) breast cancer remains a significant cause of cancer-related mortality. First-line treatment with endocrine therapy (ET) with a cyclin-dependent kinases 4 and 6 inhibitor (CDK4/6i) has become the standard of care. Data on populations that have been treated in the real-world setting may provide an insight into changes of patient characteristics and prognosis over time.
Methods
Retrospective data of patients (pts) who received CDK4/6i with ET between 2017 and 2022 at University Hospitals of Leicester NHS Trust were analysed. Patient characteristics, efficacy and toxicity outcomes were examined. Kaplan-Meier survival curves were determined using SPSS program.
Results
In all, 235 pts who were on ET in combination with Palbociclib 51% (n=119), Ribociclib 41% (n=97) and Abemaciclib 8% (n=19) were included. The median age was 62 years (33-90). De novo MBC accounted for 33% (n=78) of pts. Most (n=180, 70%) were post-menopausal. The majority 74% (n=175) had visceral disease (lung, liver, peritoneum) vs 26% (n=60) with bone-only disease. The CDK4/6i was discontinued in 48% (n=113) due to disease progression. Over half (n=135, 57%) required at least one dose reduction (DR). The most common reason for DR was neutropenia. Sixty (26%) pts remain on treatment at the time of analysis. Thirteen pts had CDK4/6i switched within 3 months of starting treatment due to toxicities. Median duration on Palbociclib (P), Ribociclbib (R), and Abemaciclib (A) was 20 months; 95% CI= 16.4-23.6, 18; 95% CI= 12.6-23.4 and 8; 95% CI= 0.7-15.3 months respectively. Median PFS between different CDK4/6i were P (24 months; 95% CI= 19.5-28.7), R (27 months; 95% CI= 20.5-33.3) and A (13 months; 95% CI= 6.8-18.9), p=0.22. The difference in median OS was statistically significant (p=0.004) between CDK4/6i; P (54 months; 95% CI= 42.4-58.8), R (46 months; 95% CI= 32.8-60.1) and A (26 months; 95% CI= 4.2-47.8).
Conclusions
CDK4/6i is safe and effective in this population with extensive burden of disease. Dose reduction did not appear to have an impact on efficacy. Survival outcomes observed were similar to randomised phase 3 clinical trials.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1288P - Neoadjuvant therapy with anti-PD-1/PD-L1 plus platinum-base chemotherapy for resectable stage II-III non-small cell lung cancer: A systematic review and meta-analysis of randomized clinical trials
Presenter: Maria Dacoregio
Session: Poster session 04
1289TiP - LANTERN study: A multi-omics digital human avatar for integrating precision medicine into clinical practice for lung cancer patients
Presenter: Emilio Bria
Session: Poster session 04
1294P - A final analysis of a phase II study of durvalumab immediately after completion of chemoradiotherapy in unresectable stage III non–small-cell lung cancer: TORG1937 (DATE study)
Presenter: Tetsuro Kondo
Session: Poster session 04
1296P - Neoadjuvant camrelizumab and apatinib in patients with resectable non-small-cell lung cancer: One-year update from a phase II trial
Presenter: Wei Guo
Session: Poster session 04
1297P - An open-label, prospective phase II study of tislelizumab in combination with chidamide as consolidation therapy in locally advanced, unresectable, stage III NSCLC
Presenter: Yi Hu
Session: Poster session 04
1298P - Chemotherapy with concurrent proton vs. photon radiotherapy in stage III NSCLC: Effects on hematological toxicity and immune therapy
Presenter: Francesco Cortiula
Session: Poster session 04
1299P - The role of radiotherapy in extensive-stage small cell lung cancer after durvalumab-based immunochemotherapy: A retrospective study
Presenter: Lingjuan Chen
Session: Poster session 04
1300P - Treatment and clinical outcome in recurrent/refractory locally advanced NSCLC following chemoradiotherapy and consolidative durvalumab
Presenter: Georg Evers
Session: Poster session 04